Skip to main content
SpringerLink
Log in

Hematopoietic Growth Factors

  • Chapter
  • First Online:
Supportive Care in Pediatric Oncology

Part of the book series: Pediatric Oncology ((PEDIATRICO))

  • 1397 Accesses

Abstract

Several recombinant human hematopoietic growth factors are approved and in clinical use but not all are approved for use in children with cancer. Here we review the evidence-based guidelines for neutrophil stimulating factors granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) as well as evidence regarding erythropoietins and platelet growth factors interleukin-11 (IL-11) and thrombopoietin (TPO)-receptor agonists. Among these hematopoietic growth factors, only G-CSF and GM-CSF are approved in children with cancer; we review the evidence regarding their use in different clinical scenarios as well as the appropriate timing and dose of therapy. Evidence regarding the current status of the other hematopoietic cytokines in regard to pediatric oncology patients is also reviewed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Aapro MS, Bohlius J, Cameron DA et al (2011) 2010 Update of EORTC Guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumors. Eur J Cancer 47:8–32

    CAS  PubMed  Google Scholar 

  • Aapro M, Jeklmann W, Constantinescu SN, Leyland-Jones B (2012) Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer. Br J Cancer 106:1249–1258

    PubMed Central  CAS  PubMed  Google Scholar 

  • Abdelrazik N, Fouda M (2007) Once weekly recombinant human erythropoietin treatment for cancer-induced anemia in children with acute lymphoblastic leukemia receiving maintenance chemotherapy: a randomized case-controlled study. Hematology 12:533–541

    CAS  PubMed  Google Scholar 

  • Alonzo TA, Kobrinsky NL, Aledo A et al (2002) Impact of granulocyte colony-stimulating factor use during induction for acute myelogenous leukemia in children: a report from the Children’s Cancer Group. J Pediatr Hematol Oncol 24:627–635

    PubMed  Google Scholar 

  • Andemariam B, Psaila B, Bussel JB (2007) Novel thrombopoietic agents. Hematology Am Soc Hematol Educ Program 106–113

    Google Scholar 

  • André N, Kababri ME, Bertrand P et al (2007) Safety and efficacy of pegfilgrastim in children with cancer receiving myelosuppressive chemotherapy. Anticancer Drugs 18:277–281

    PubMed  Google Scholar 

  • Angiolillo AL, Davenport V, Bonilla MA et al (2005) A phase I clinical, pharmacologic, and biologic study of thrombopoietin and granulocyte colony-stimulating factor in children receiving ifosfamide, carboplatin, and etoposide chemotherapy for recurrent or refractory solid tumors: a Children’s Oncology Group experience. Clin Cancer Res 11:2644–2650

    CAS  PubMed  Google Scholar 

  • Antman KS, Griffin JD, Elias A et al (1988) Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med 319:593–598

    CAS  PubMed  Google Scholar 

  • Basser RL, Rasko JE, Clarke K et al (1997) Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer. Blood 89:3118–3128

    CAS  PubMed  Google Scholar 

  • Basser RL, Underhill C, Davis I et al (2000) Enhancement on platelet recovery after myelosuppressive chemotherapy by recombinant human megakaryocyte growth and development factor in patients with advanced cancer. J Clin Oncol 18:2852–2861

    CAS  PubMed  Google Scholar 

  • Basser RL, O’Flaherty E, Green M et al (2002) Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood 99:2599–2602

    CAS  PubMed  Google Scholar 

  • Batra S, Perelman N, Luck LR et al (2003) Pediatric tumor cells express erythropoietin and a functional erythropoietin receptor that promotes angiogenesis and tumor cell survival. Lab Invest 83:1477–1487

    CAS  PubMed  Google Scholar 

  • Bennett CL, Silver SM, Djulbegovic B et al (2008) Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 299:914–924

    CAS  PubMed  Google Scholar 

  • Bhatia M, Davenport V, Cairo MS (2007) The role of interleukins-11 to prevent chemotherapy-induced thrombocytopenia in patients with solid tumors, lymphoma, acute myeloid leukemia and bone marrow failure syndromes. Leuk Lymphoma 48:9–15

    CAS  PubMed  Google Scholar 

  • Blumer J, Berg S, Adamson PC et al (2007) Pharmacokinetic evaluation of darbepoetin alfa for the treatment of pediatric patients with chemotherapy-induced anemia. Pediatr Blood Cancer 49:687–693

    PubMed  Google Scholar 

  • Bohlius J, Wilson J, Seidenfeld J et al (2006) Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 98:708–714

    CAS  PubMed  Google Scholar 

  • Bohlius J, Schmidlin K, Brillant C et al (2009) Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomized trials. Lancet 373:1532–1542

    CAS  PubMed  Google Scholar 

  • Bohlius J, Schmidlin K, Brillant C et al (2010) Erythropoietin or darbepoetin for patients with cancer—meta-analysis based on individual patient data. Cochrane Database Syst Rev (3):CD007303

    Google Scholar 

  • Bokemeyer C (2004) EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 40:2201–2216

    CAS  PubMed  Google Scholar 

  • Bonadonna G, Valagussa P (1981) Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 304:10–15

    CAS  PubMed  Google Scholar 

  • Borinstein SC, Pollard J, Winter L, Hawkins DS (2009) Pegfilgrastim for prevention of chemotherapy-associated neutropenia in pediatric patients with solid tumors. Pediatr Blood Cancer 53:375–378

    PubMed  Google Scholar 

  • Bronchud MH, Howell A, Crowther D et al (1989) The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer. Br J Cancer 60:121–125

    PubMed Central  CAS  PubMed  Google Scholar 

  • Broudy VC, Lin NL, Kaushansky K (1995) Thrombopoietin (c-mpl ligand) acts synergistically with erythropoietin, stem cell factor, and interleukin-11 to enhance murine megakaryocyte colony growth and increases megakaryocyte ploidy in vitro. Blood 85:1719–1726

    CAS  PubMed  Google Scholar 

  • Bussel JB, Kuter DJ, George JN et al (2006) AMG 531, a thrombopoiesis-stimulating protein for chronic ITP. N Engl J Med 355:1672–1681

    CAS  PubMed  Google Scholar 

  • Bussel JB, Cheng G, Saleh MN et al (2007) Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 357:2237–2247

    CAS  PubMed  Google Scholar 

  • Bussel JB, Kuter DJ, Pullarkat V et al (2009) Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 113:2161–2171

    CAS  PubMed  Google Scholar 

  • Bussel JB, Buchanan GR, Nugent DJ et al (2011) A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia. Blood 118:28–36

    CAS  PubMed  Google Scholar 

  • Büyükpamukçu M, Varan A, Kutluk T et al (2002) Is epoetin alfa a treatment option for chemotherapy-related anemia in children? Med Pediatr Oncol 39:455–458

    PubMed  Google Scholar 

  • Cairo MS, Shen V, Krailo MD et al (2001) Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: a children’s cancer group report. J Pediatr Hematol Oncol 23:30–38

    CAS  PubMed  Google Scholar 

  • Cairo MS, Davenport V, Bessmertny O et al (2004) Phase I/II dose escalation study of recombinant human interleukin-11 following ifosfamide, carboplatin and etoposide in children, adolescents and young adults with solid tumours or lymphoma: a clinical, haematological and biological study. Br J Haematol 128:49–58

    Google Scholar 

  • Ciernik IF, Schanz U, Gmür J (1999) Delaying treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for hematological malignancies: a prospective randomized trial. Bone Marrow Transplant 24:147–151

    CAS  PubMed  Google Scholar 

  • Clark OA, Lyman GH, Castro AA et al (2005) Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol 23:4198–4214

    CAS  PubMed  Google Scholar 

  • Çorapcioglu F, Aksu G, Basar E et al (2008) Recombinant human erythropoietin beta therapy: an effective strategy to reduce transfusion requirement in children receiving anticancer therapy. Pediatr Hematol Oncol 25:509–521

    PubMed  Google Scholar 

  • Cripe LD, Rader K, Tallman MS et al (2006) Phase II trial of subcutaneous recombinant human interleukin 11 with subcutaneous recombinant human granulocyte-macrophage colony stimulating factor in patients with acute myeloid leukemia (AML) receiving high-dose cytarabine during induction: ECOG 3997. Leuk Res 30:823–827

    CAS  PubMed  Google Scholar 

  • Csáki C, Ferencz T, Schuler D et al (1998) Recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia in children with malignant solid tumors. Eur J Cancer 34:364–367

    PubMed  Google Scholar 

  • Demetri GD (2001) Targeted approaches for the treatment of thrombocytopenia. Oncologist 6:15–23

    CAS  PubMed  Google Scholar 

  • Djulbegovic B, Frohlich A, Bennett CL (2005) Acting on imperfect evidence: how much regret are we ready to accept? J Clin Oncol 23:6822–6825

    PubMed  Google Scholar 

  • Du X, Williams DA (1997) Interleukin-11: review of molecular, cell biology, and clinical use. Blood 89:3897–3908

    CAS  PubMed  Google Scholar 

  • Dubois RW, Pinto LA, Bernal M et al (2004) Benefits of GM-CSF versus placebo or G-CSF in reducing chemotherapy-induced complications: a systematic review of the literature. Support Care Cancer 2:34–41

    Google Scholar 

  • Durmaz O, Demirkaya M, Sevinir B (2011) Recombinant human erythropoietin β: the effect of weekly dosing on anemia, quality of life, and long-term outcomes in pediatric cancer patients. Pediatr Hematol Oncol 28:461–468

    CAS  PubMed  Google Scholar 

  • Eguchi K, Shinkai T, Sasaki Y et al (1990) Subcutaneous administration of recombinant human granulocyte colony-stimulating factor (KRN8601) in intensive chemotherapy in patients with advanced lung cancer. Jpn J Cancer Res 81:1168–1174

    CAS  PubMed  Google Scholar 

  • Elafy MS, Abdelmaksoud AA, Eltonbary KY (2011) Romiplostim in children with chronic refractory ITP: randomized placebo controlled study. Ann Hematol 90:1341–1344

    Google Scholar 

  • ESMO Guidelines Working Group, Greil R, Psenak O (2007) Hematopoietic growth factors: ESMO recommendations for the application. Ann Oncol 18:ii89–ii91

    Google Scholar 

  • Fanucchi M, Glapsy J, Crawford J et al (1997) Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N Engl J Med 336:404–409

    CAS  PubMed  Google Scholar 

  • Farese AM, Smith WG, Giri JG et al (2001) Promegapoietin-1a, an engineered chimeric IL-3 and Mpl-L receptor agonist, stimulates hematopoietic recovery in conventional and abbreviated schedules following radiation-induced myelosuppression in nonhuman primates. Stem Cells 19:329–338

    CAS  PubMed  Google Scholar 

  • Fernandez MC, Krailo MD, Gerbing RR et al (2000) A phase I dose escalation of combination chemotherapy with granulocyte-macrophage-colony stimulating factor in patients with neuroblastoma. Cancer 88:2838–2844

    CAS  PubMed  Google Scholar 

  • Feusner J (2009) Guidelines for Epo use in children with cancer. Pediatr Blood Cancer 53:308–309

    PubMed  Google Scholar 

  • Feusner J, Hastings C (2002) Recombinant human erythropoietin in pediatric oncology: a review. Med Pediatr Oncol 39:463–468

    PubMed  Google Scholar 

  • Fox E, Widemann BC, Hawkins DS et al (2009) Randomized trial and pharmacokinetic study of pegfilgrastim versus filgrastim after dose-intensive chemotherapy in young adults and children with sarcomas. Clin Cancer Res 15:7361–7367

    PubMed Central  CAS  PubMed  Google Scholar 

  • Galliford JW, Malasana R, Farrington K (2005) Switching from subcutaneous to intravenous erythropoietin α in haemodialysis patients requires a major dose increase. Nephrol Dial Transplant 20:1956–1962

    CAS  PubMed  Google Scholar 

  • Gernsheimer T (2008) The pathophysiology of ITP revisited: ineffective thrombopoiesis and the emerging role of thrombopoietin receptor agonists in the management of chronic immune thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program 219–226

    Google Scholar 

  • Giles FJ, Kantarijian HM, Cortes JE et al (2005) Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes. Leuk Res 29:649–652

    CAS  PubMed  Google Scholar 

  • Glasby J, Crawford J, Vansteenkiste J et al (2010) Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer 102:301–315

    Google Scholar 

  • Glaspy J, Cavill I (1999) Role of iron in optimizing responses of anemic cancer patients to erythropoietin. Oncology 13:461–473; discussion 477–478, 483–488

    CAS  PubMed  Google Scholar 

  • Gordon MS, McCaskill-Stevens WJ, Battiato LA et al (1996) A phase I trial of recombinant human interleukin-11 (neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy. Blood 87:3615–3624

    CAS  PubMed  Google Scholar 

  • Gurion R, Belnik-Plitman Y, Gafter-Gvili A et al (2012) Colony-stimulating factors for prevention and treatment of infectious complications in patients with acute myelogenous leukemia. Cochrane Database Syst Rev (6):CD008238

    Google Scholar 

  • Guyatt G, Gutterman D, Baumann MH et al (2006) Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians Task Force. Chest 129:174–181

    PubMed  Google Scholar 

  • Hägglund H, Ringdén O, Oman S et al (1999) A prospective randomized trial of Filgrastim (r-metHuG-CSF) given at different times after unrelated bone marrow transplantation. Bone Marrow Transplant 24:831–836

    PubMed  Google Scholar 

  • Henke M, Laszig R, Rübe C et al (2003) Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362:1255–1260

    CAS  PubMed  Google Scholar 

  • Hofmann WK, Seipelt G, Langerhan S et al (2002) Prospective randomized trial to evaluate two delayed granulocyte colony stimulating factor administration schedules after high-dose cytarabine therapy in adult patients with acute lymphoblastic leukemia. Ann Hematol 81:570–574

    CAS  PubMed  Google Scholar 

  • Holmes FA, O’Shaughnessy JA, Vukelja S et al (2002) Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 20:727–731

    CAS  PubMed  Google Scholar 

  • Honkoop AH, Hoekman K, Wagstaff J et al (1996) Continuous infusion or subcutaneous injection of granulocyte-macrophage colony-stimulating factor: increased efficacy and reduced toxicity when given subcutaneously. Br J Cancer 74:1132–1136

    PubMed Central  CAS  PubMed  Google Scholar 

  • Isaacs C, Robert NJ, Bailey FA et al (1997) Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin. J Clin Oncol 15:3368–3377

    CAS  PubMed  Google Scholar 

  • Jelkmann W (1992) Erythropoietin: structure, control of production, and function. Physiol Rev 72:449–489

    CAS  PubMed  Google Scholar 

  • Jenkins JM, Williams D, Deng Y et al (2007) Phase I clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood 109:4739–4741

    CAS  PubMed  Google Scholar 

  • Jones CA, Shaw PJ, Stevens MM (1995) Use of granulocyte colony stimulating factor to reduce the toxicity of super-VAC chemotherapy in advanced solid tumours in childhood. Med Pediatr Oncol 25:84–89

    CAS  PubMed  Google Scholar 

  • Jones SE, Khandelwal P, McIntyre K et al (1999) Randomized, double-blind, placebo-controlled trial to evaluate the hematopoietic growth factor PIXY321 after moderate-dose fluorouracil, doxorubicin, and cyclophosphamide in stage II and III breast cancer. J Clin Oncol 17:3025–3032

    CAS  PubMed  Google Scholar 

  • Kaneko T, Takaku F, Ogawa M (1991) Outline of clinical studies on recombinant human granulocyte colony stimulating factor (KRN 8601) in Japan. Tokai J Exp Clin Med 16:51–61

    CAS  PubMed  Google Scholar 

  • Kaufman JS, Reda DJ, Fye CL et al (1998) Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients. N Engl J Med 339:578–583

    CAS  PubMed  Google Scholar 

  • Kaushansky K (1998) Thrombopoietin. N Engl J Med 339:746–754

    CAS  PubMed  Google Scholar 

  • Kaushansky K (2005) The molecular mechanisms that control thrombopoiesis. J Clin Invest 115:3339–3347

    PubMed Central  CAS  PubMed  Google Scholar 

  • Kaushansky K, Lok K, Holly RD et al (1994) Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature 369:568–571

    CAS  PubMed  Google Scholar 

  • Kawakami M, Tsutsumi M, Kumakawa T et al (1990) Levels of serum granulocyte colony-stimulating factor in patients with infections. Blood 76:1962–1964

    CAS  PubMed  Google Scholar 

  • Krantz SB (1991) Erythropoietin. Blood 77:419–434

    CAS  PubMed  Google Scholar 

  • Kubota M, Akiyama Y, Mikawa H, Tsutsui T (1995) Comparative effect of 100 versus 250 micrograms/m2/day of G-CSF in pediatric patients with neutropenia induced by chemotherapy. Pediatr Hematol Oncol 12:393–397

    CAS  PubMed  Google Scholar 

  • Kushner BH, LaQuaglia MP, Bonilla MA et al (1994) Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age. J Clin Oncol 12:2607–2613

    CAS  PubMed  Google Scholar 

  • Kushner BH, Meyers PA, Gerald WL et al (1995) Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing’s sarcoma, in children and young adults. J Clin Oncol 13:2796–2804

    CAS  PubMed  Google Scholar 

  • Kushner BH, Heller G, Kramer K et al (2000) Granulocyte-colony stimulating factor and multiple cycles of strongly myelosuppressive alkylator-based combination chemotherapy in children with neuroblastoma. Cancer 89:2122–2130

    CAS  PubMed  Google Scholar 

  • Kuter DJ (2007) New thrombopoietic growth factors. Blood 109:4607–4616

    PubMed Central  CAS  PubMed  Google Scholar 

  • Kuter DJ, Beeler DL, Rosenberg RD (1994) The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production. Proc Natl Acad Sci U S A 91:11104–11108

    PubMed Central  CAS  PubMed  Google Scholar 

  • Kuter DJ, Cebon J, Harker LA et al (1999) Platelet growth factors: potential impact on transfusion medicine. Transfusion 39:321–332

    CAS  PubMed  Google Scholar 

  • Kuter DJ, Bussel JB, Lyons RM et al (2008) Efficacy of romiplostim in patients with chronic immune thrombocytopenia purpura: a double-blind randomized controlled trial. Lancet 371:395–403

    CAS  PubMed  Google Scholar 

  • Kuter DJ, Bussel JB, Newland A et al (2013) Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. Br J Haematol 161:411–423

    CAS  PubMed  Google Scholar 

  • Kwak LW, Halpern J, Olshen RA et al (1990) Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol 8:963–977

    CAS  PubMed  Google Scholar 

  • Layton JE, Hockman H, Sheridan WP et al (1989) Evidence for a novel in vivo control mechanism of granulopoiesis: mature cell-related control of a regulatory growth factor. Blood 74:1303–1307

    CAS  PubMed  Google Scholar 

  • Lee KH, Lee JH, Choi SJ et al (1999) Randomized comparison of two different schedules of granulocyte colony-stimulating factor administration after allogeneic bone marrow transplantation. Bone Marrow Transplant 24:591–599

    CAS  PubMed  Google Scholar 

  • Lehrnbecher T, Welte K (2002) Haematopoietic growth factors in children with neutropenia. Br J Haematol 116:28–56

    CAS  PubMed  Google Scholar 

  • Lehrnbecher T, Zimmermann M, Reinhardt D et al (2007) Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia. Blood 109:936–943

    CAS  PubMed  Google Scholar 

  • Leyland-Jones B (2003) Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 4:459–460

    PubMed  Google Scholar 

  • Li J, Yang C, Xia Y et al (2001) Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 98:3241–3248

    CAS  PubMed  Google Scholar 

  • Lieschke GJ, Burgess AW (1992) Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (1). N Engl J Med 327:28–35

    CAS  PubMed  Google Scholar 

  • Lydaki E, Bolonaki E, Staikaki E et al (1995) Efficacy of recombinant human granulocyte colony-stimulating factor and recombinant human granulocyte-macrophage colony-stimulating factor in neutropenic children with malignancies. Pediatr Hematol Oncol 12:551–558

    CAS  PubMed  Google Scholar 

  • Marec-Berard P, Chastagner P, Kassab-Chahmi D et al (2009) 2007 Standards, Options, and Recommendations: use of erythropoiesis-stimulating agents (ESA: epoetin alfa, epoetin beta, and darbepoetin) for the management of anemia in children with cancer. Pediatr Blood Cancer 53:7–12

    PubMed  Google Scholar 

  • Masuda S, Nagao M, Sasaki R (1999) Erythropoietic, neurotrophic, and angiogenic functions of erythropoietin and regulation of erythropoietin production. Int J Hematol 70:1–6

    CAS  PubMed  Google Scholar 

  • Meropol NJ, Miller LL, Korn EL et al (1992) Severe myelosuppression resulting from concurrent administration of granulocyte colony-stimulating factor and cytotoxic chemotherapy. J Natl Cancer Inst 84:1201–1203

    CAS  PubMed  Google Scholar 

  • Michel G, Landman-Parker J, Auclerc MF et al (2000) Use of recombinant human granulocyte colony-stimulating factor to increase chemotherapy dose-intensity: a randomized trial in very high-risk childhood acute lymphoblastic leukemia. J Clin Oncol 18:1517–1524

    CAS  PubMed  Google Scholar 

  • Michon JM, Hartmann O, Bouffet E et al (1998) An open-label, multicentre, randomised phase 2 study of recombinant human granulocyte colony-stimulating factor (filgrastim) as an adjunct to combination chemotherapy in paediatric patients with metastatic neuroblastoma. Eur J Cancer 34:1063–1069

    CAS  PubMed  Google Scholar 

  • Milano-Bausset E, Gaudart J, Rome A et al (2009) Retrospective comparison of neutropenia in children with Ewing sarcoma treated with chemotherapy and granulocyte colony-stimulating factor (G-CSF) or pegylated G-CSF. Clin Ther 31:2388–2395

    CAS  PubMed  Google Scholar 

  • Miller LL, Korn EL, Stevens DS et al (1999) Abrogation of the hematological and biological activities of the interleukin-3/granulocyte-macrophage colony-stimulating factor fusion protein PIXY321 by neutralizing anti-PIXY321 antibodies in cancer patients receiving high-dose carboplatin. Blood 93:3250–3258

    CAS  PubMed  Google Scholar 

  • Mitchell PL, Morland B, Stevens MC et al (1997) Granulocyte colony-stimulating factor in established febrile neutropenia: a randomized study of pediatric patients. J Clin Oncol 15:1163–1170

    CAS  PubMed  Google Scholar 

  • Musashi M, Yang YC, Paul SR et al (1991) Direct and synergistic effects of interleukin 11 on murine hemopoiesis in culture. Proc Natl Acad Sci U S A 88:765–769

    PubMed Central  CAS  PubMed  Google Scholar 

  • Muskowitz CH, Hamlin PA, Gabrilove J et al (2007) Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma. Ann Oncol 18:1842–1850

    Google Scholar 

  • O’Shaughnessy JA, Tolcher A, Riseberg D et al (1996) Prospective, randomized trial of 5-fluorouracil, leucovorin, doxorubicin, and cyclophosphamide chemotherapy in combination with the interleukin-3/granulocyte-macrophage colony-stimulating factor (GM-CSF) fusion protein (PIXY321) versus GM-CSF in patients with advanced breast cancer. Blood 87:2205–2211

    PubMed  Google Scholar 

  • Orazi A, Copper RJ, Tong J et al (1996) Effects of recombinant human interleukin-11 (Neumega rhIL-11 growth factor) on megakaryocytopoiesis in human bone marrow. Exp Hematol 24:1289–1297

    CAS  PubMed  Google Scholar 

  • Ozkaynak MF, Krailo M, Chen Z et al (2005) Randomized comparison of antibiotics with and without granulocyte colony-stimulating factor in children with chemotherapy-induced febrile neutropenia: a report from the Children’s Oncology Group. Pediatr Blood Cancer 45:274–280

    PubMed  Google Scholar 

  • Porter JC, Leahey A, Polise K et al (1996) Recombinant human erythropoietin reduces the need for erythrocyte and platelet transfusions in pediatric patients with sarcoma: a randomized, double-blind, placebo-controlled trial. J Pediatr 129:656–660

    CAS  PubMed  Google Scholar 

  • Rahiala J, Perkkio M, Riikonen P (1999) Prospective and randomized comparison of early versus delayed prophylactic administration of granulocyte colony-stimulating factor (filgrastim) in children with cancer. Med Pediatr Oncol 32:326–330

    CAS  PubMed  Google Scholar 

  • Razzouk BI, Hord JD, Hockenberry M et al (2006) Double-blind, placebo-controlled study of quality of life, hematologic end points, and safety of weekly epoetin alfa in children with cancer receiving myelosuppressive chemotherapy. J Clin Oncol 24:3583–3589

    CAS  PubMed  Google Scholar 

  • Riikonen P, Saarinen UM, Mäkipernaa A et al (1994) Recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of febrile neutropenia: a double blind placebo-controlled study in children. Pediatr Infect Dis J 13:197–202

    CAS  PubMed  Google Scholar 

  • Rizzo JD, Brouwers M, Hurley P et al (2010) American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol 28:4996–5010

    PubMed  Google Scholar 

  • Saarinen-Pihkala UM, Lanning M, Perkkiö M et al (2000) Granulocyte-macrophage colony-stimulating factor support in therapy of high-risk acute lymphoblastic leukemia in children. Med Pediatr Oncol 34:319–327

    CAS  PubMed  Google Scholar 

  • Sartelet H, Fabre M, Castaing M et al (2007) Expression of erythropoietin and its receptor in neuroblastomas. Cancer 110:1096–1105

    PubMed  Google Scholar 

  • Sasse EC, Sasse AD, Brandalise SR et al (2005) Colony-stimulating factors for prevention of myelosuppressive therapy-induced febrile neutropenia in children with acute lymphoblastic leukaemia. Cochrane Database Syst Rev (3):CD004139

    Google Scholar 

  • Schaison G, Eden OB, Henze G et al (1998) Recommendations on the use of colony-stimulating factors in children: conclusions of a European panel. Eur J Pediatr 157:955–966

    CAS  PubMed  Google Scholar 

  • Schrijvers D, De Samblanx H, Roila F, ESMO Guidelines Working Group (2010) Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO Clinical Practice Guidelines for use. Ann Oncol 21:v244–v247

    PubMed  Google Scholar 

  • Shankar AG (2008) The role of recombinant erythropoietin in childhood cancer. Oncologist 13:157–166

    CAS  PubMed  Google Scholar 

  • Smith TJ, Khatcheressian J, Lyman GH et al (2006) 2006 update of recommendation for the use of white blood cell growth factors: an evidence–based clinical practice guideline. J Clin Oncol 24:3187–3205

    CAS  PubMed  Google Scholar 

  • Spunt SL, Irving H, Frost J et al (2010) Phase II, randomized, open-label study of pegfilgrastim-supported VDC/IE chemotherapy in pediatric sarcoma patients. J Clin Oncol 28:1329–1336

    PubMed Central  CAS  PubMed  Google Scholar 

  • Stute N, Furman WL, Schell M et al (1995) Pharmacokinetics of recombinant human granulocyte-macrophage colony-stimulating factor in children after intravenous and subcutaneous administration. J Pharm Sci 84:824–828

    CAS  PubMed  Google Scholar 

  • Sung L, Nathan PC, Lange B et al (2004) Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials. J Clin Oncol 22:3350–3356

    CAS  PubMed  Google Scholar 

  • Sung L, Aplenc R, Alonzo TA et al (2013) Effectiveness of supportive care measures to reduce infections in pediatric AML: a report from the Children’s Oncology Group. Blood 121:3573–3577

    PubMed Central  CAS  PubMed  Google Scholar 

  • Takeshita A, Shinjo K, Higuchi M et al (2000) Quantitative expression of erythropoietin receptor (EPO-R) on acute leukaemia cells: relationships between the amount of EPO-R and CD phenotypes, in vitro proliferative response, the amount of other cytokine receptors and clinical prognosis. Japan Adult Leukaemia Study Group. Br J Haematol 108:55–63

    CAS  PubMed  Google Scholar 

  • te Poele E, Kamps W, Tamminga R et al (2005) Pegfilgrastim in pediatric cancer patients. J Pediatr Hematol Oncol 27:627–629

    Google Scholar 

  • Tepler I, Elias L, Smith JW et al (1996) A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood 87:3607–3614

    CAS  PubMed  Google Scholar 

  • Teramura M, Kobayashi S, Hoshino S et al (1992) Interleukin-11 enhances human megakaryocytopoiesis in vitro. Blood 79:327–331

    CAS  PubMed  Google Scholar 

  • Usuki K, Urabe A, Ikeda Y et al (2007) A multicenter randomized, double-blind, placebo-controlled late-phase II/III study of recombinant human interleukin 11 in acute myelogenous leukemia. Int J Hematol 85:59–69

    CAS  PubMed  Google Scholar 

  • Vadhan-Raj S, Verschraegen CF, Bueso-Ramos C et al (2000) Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer. Ann Intern Med 132:364–368

    CAS  PubMed  Google Scholar 

  • Vadhan-Raj S, Patel S, Bueso-Ramos C et al (2003) Importance of predosing of recombinant human thrombopoietin to reduce chemotherapy-induced early thrombocytopenia. J Clin Oncol 21:3158–3167

    CAS  PubMed  Google Scholar 

  • Vadhan-Raj S, Cohen V, Bueso-Ramos C (2005) Thrombopoietic growth factors and cytokines. Curr Hematol Rep 4:137–144

    CAS  PubMed  Google Scholar 

  • Vercaigne LM, Collins DM, Penner SB (2005) Conversion from subcutaneous to intravenous erythropoietin in a hemodialysis population. J Clin Pharmacol 45:895–900

    CAS  PubMed  Google Scholar 

  • Vredenburgh JJ, Hussein A, Fisher D et al (1998) A randomized trial of recombinant human interleukin-11 following autologous bone marrow transplantation with peripheral blood progenitor cell support in patients with breast cancer. Biol Blood Marrow Transplant 4:134–141

    CAS  PubMed  Google Scholar 

  • Wagner L, Billups CA, Furman WL et al (2004) Combined use of erythropoietin and granulocyte colony-stimulating factor does not decrease blood transfusion requirements during induction therapy for high-risk neuroblastoma: a randomized controlled trial. J Clin Oncol 22:1886–1893

    CAS  PubMed  Google Scholar 

  • Wendelin G, Lackner H, Schwinger W et al (2005) Once-per-cycle pegfilgrastim versus daily filgrastim in pediatric patients with Ewing Sarcoma. J Pediatr Hematol Oncol 27:449–451

    PubMed  Google Scholar 

  • White L, McCowage G, Kannourakis G et al (1994) Dose-intensive cyclophosphamide with etoposide and vincristine for pediatric solid tumors: a phase I/II pilot study by the Australia and New Zealand Childhood Cancer Study Group. J Clin Oncol 12:522–531

    CAS  PubMed  Google Scholar 

  • Wittman B, Horan J, Lyman G (2006) Prophylactic colony-stimulating factors in children receiving myelosuppressive chemotherapy: a meta-analysis of randomized controlled trials. Cancer Treat Rev 32:289–303

    CAS  PubMed  Google Scholar 

  • Womer RB, West DC, Krailo MD et al (2012) Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children’s Oncology Group. J Clin Oncol 30:4148–4154

    PubMed Central  CAS  PubMed  Google Scholar 

  • Woods WG, Kobirnsky N, Buckley J et al (1993) Intensively timed induction therapy followed by autologous or allogeneic bone marrow transplantation for children with acute myeloid leukemia or myelodysplastic syndrome: a Children’s Cancer Group pilot study. J Clin Oncol 11:1448–1457

    CAS  PubMed  Google Scholar 

  • Yasuda Y, Fujita Y, Matsuo T et al (2003) Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis 24:1021–1029

    CAS  PubMed  Google Scholar 

  • Yilmaz D, Çetingül N, Kantar M et al (2004) A single institutional experience: is epoetin alpha effective in anemic children with cancer? Pediatr Hematol Oncol 21:1–8

    CAS  PubMed  Google Scholar 

  • Zamboni WC, Stewart CE (2002) An overview of the pharmacokinetic disposition of darbepoetin alfa. Pharmacotherapy 22:133S–140S

    CAS  PubMed  Google Scholar 

  • Zeuner A, Signore M, Martinetti D et al (2007) Chemotherapy-induced thrombocytopenia derives from the selective death of megakaryocyte progenitors and can be rescued by stem cell factor. Cancer Res 67:4767–4773

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology/Oncology, Children’s Hospital and Research Center Oakland, Oakland, CA, USA

    Anurag K. Agrawal MD

  2. Pediatric Hematology/Oncology, Children’s Hospital Medical Center of Akron, One Perkins Square, Akron, OH, 44308, USA

    Jeffrey D. Hord MD

Authors
  1. Anurag K. Agrawal MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jeffrey D. Hord MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jeffrey D. Hord MD .

Editor information

Editors and Affiliations

  1. Department of Hematology and Oncology, Childrens Hospital & Research Center Oak, Oakland, California, USA

    James H. Feusner

  2. Hematology/Oncology, Children's Hospital and Research Center, Oakland, California, USA

    Caroline A. Hastings

  3. Hematology/Oncology, Children's Hospital and Research Center, Oakland, California, USA

    Anurag K. Agrawal

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Berlin Heidelberg

About this chapter

Cite this chapter

Agrawal, A.K., Hord, J.D. (2015). Hematopoietic Growth Factors. In: Feusner, J., Hastings, C., Agrawal, A. (eds) Supportive Care in Pediatric Oncology. Pediatric Oncology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-44317-0_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-44317-0_15

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-44316-3

  • Online ISBN: 978-3-662-44317-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation